Usage: BRENZAVVY is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes mellitus.
cycloset
(bromocriptine mesylate)
Santarus, Inc.
Usage: CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not for use in type 1 diabetes or diabetic ketoacidosis, and its efficacy is limited with certain other medications.
invokamet
(canagliflozin and metformin hydrochloride)
Janssen Pharmaceuticals, Inc.
Usage: INVOKAMET and INVOKAMET XR are indicated as adjuncts to diet and exercise for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes mellitus. Canagliflozin component reduces risks of major cardiovascular events and kidney disease in specific patient populations.
janumet
(SITAGLIPTIN and METFORMIN HYDROCHLORIDE)
Merck Sharp & Dohme LLC
Usage: JANUMET is indicated for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It should not be used in type 1 diabetes and has not been studied in patients with a history of pancreatitis.
janumet
(sitagliptin and metformin hydrochloride)
Merck Sharp & Dohme LLC
Usage: JANUMET XR is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not for use in patients with type 1 diabetes or those with a history of pancreatitis.
januvia
(sitagliptin)
Merck Sharp & Dohme LLC
Usage: JANUVIA® is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It should not be used in type 1 diabetes and has not been studied in patients with a history of pancreatitis.
jardiance
(Empagliflozin)
Boehringer Ingelheim Pharmaceuticals, Inc.
Usage: JARDIANCE is indicated for reducing the risk of cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.
mounjaro
(tirzepatide)
Eli Lilly and Company
Usage: MOUNJARO® is indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. It is not studied in patients with pancreatitis and is not indicated for type 1 diabetes mellitus.
onglyza
(SAXAGLIPTIN)
AstraZeneca Pharmaceuticals LP
Usage: ONGLYZA is indicated for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, both as monotherapy and in combination with other medications.
rybelsus
(Oral Semaglutide)
Novo Nordisk
Usage: RYBELSUS is indicated for improving glycemic control in adults with type 2 diabetes mellitus, used alongside diet and exercise. It is not recommended for patients with type 1 diabetes mellitus.